ClinicalTrials.gg
Active, not recruitingNCT06041386REIMAGINEUpdated Nov 10, 2026

REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

A Phase 4 interventional study of Mepolizumab and Spirometry in Asthma, sponsored by GlaxoSmithKline. Active, not recruiting at 65 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Other

How we know

Updated Nov 10, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
177
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 28 studies testing mepolizumab in Asthma — 2 open to participants now, 3 under way, none of them phase 3. mepolizumab · Asthma.

Enrollment
10th of 28
177 · median 100
Started
2024
the only one that year
Phase 4
9 of 28
2 open now
Registered
27th of 28
by date
Lead sponsor
15 of 28
GlaxoSmithKline

Among the 28 studies testing mepolizumab in Asthma, this one is the 10th largest by enrollment, is the only one that started in 2024, is one of 9 in phase 4, and was the 27th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

2 of the 28 studies testing mepolizumab in Asthma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About mepolizumab

mepolizumab: first FDA approval 2015 (NUCALA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing mepolizumab in Asthma, or all of them as a file.
02

Study summary

This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Severe asthma
  • Eosinophilic phenotype
  • Oral corticosteroids (OCS)
  • Asthma exacerbations
  • Clinical remission
  • NUCALA
  • Mepolizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has a confirmed asthma diagnosis and has been prescribed NUCALA by their physician for the treatment of asthma, as per local label. NUCALA can be initiated up to 7 days prior to study enrollment.
  • No NUCALA use in the 6 months prior to enrollment.
  • Participants with greater than or equal to (≥)60 percentage (%) predicted (FEV1) and less than or equal to (≤)4 exacerbations per year, as confirmed by the physician.
  • Other local prescription criteria of NUCALA not described above at NUCALA initiation (e.g., local reimbursement criteria).
  • Written

Exclusion criteria

Exclusion Criteria:

  • Investigator concerns about participant's willingness to adhere to biologic treatment for any reason (e.g., cost, behavior, difficulty with access to healthcare)
  • Participants currently on maintenance OCS or intramuscular .
  • Participants using omalizumab, reslizumab, dupilumab, tezepelumab, or benralizumab within the 6 months prior to enrollment
  • Participants participating in an interventional study with a treatment intervention
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
177 participants (actual)

Study arms

  • Other
    Group 1

    Participants with a clinical diagnosis of Severe asthma prescribed Mepolizumab as part of routine care.

    Drug: Mepolizumab · Other: Spirometry

Interventions

  • Mepolizumab will be prescribed based on physician decision.

  • OtherSpirometry

    Lung function via spirometry will be collected.

06

What researchers measure

Primary outcomes

  1. Percentage (%) of Participants Achieving 4-Component Clinical Remission

    4-component clinical remission is defined as (a) No clinically significant asthma exacerbations (b) No OCS use for asthma (c) Well controlled asthma based on an Asthma Control Test (ACT) (d) No clinically significant deterioration of lung function.

    Time frame: At month 12

Secondary outcomes

  1. Annualized Rates of Clinically Significant Asthma Exacerbations (CSE) and CSE Leading to Hospitalization/ Emergency Room (ER) Visits

    CSE is defined as a deterioration in asthma requiring (1) the initiation of systemic corticosteroids and/or (2) an ER visit and/or hospital admission.

    Time frame: At month 12

  2. Percentage of Participants Achieving OCS Sparing Remission

    OCS sparing is defined as (a) No clinically significant asthma exacerbations during the period of interest (b) No OCS use for asthma at the time point of interest.

    Time frame: At month 12

  3. Percentage of Participants Achieving 3-Component Clinical Remission

    3-component clinical remission is defined as (a) No clinically significant asthma exacerbations (b) No OCS use for asthma (c) Well controlled asthma based on an ACT

    Time frame: At month 12

  4. Mean Change from Baseline in Mini-Asthma Quality of Life Questionnaire (AQLQ) Overall Score

    The mini-AQLQ overall score is a reduced version of the AQLQ which includes 15 items. The minimally clinically important difference (MCID) is 0.5. The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability

    Time frame: Baseline and at month 12

07

Study locations

65 sites
  • GSK Investigational Site
    La Jolla, California 92037, United States
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    Aurora, Colorado 71105, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80923, United States
  • GSK Investigational Site
    New Haven, Connecticut 06510, United States
  • GSK Investigational Site
    Homestead, Florida 33032-8185, United States
  • GSK Investigational Site
    Jacksonville, Florida 32209, United States
  • GSK Investigational Site
    Miami, Florida 33125, United States
  • GSK Investigational Site
    Plantation, Florida 33317, United States
  • GSK Investigational Site
    Adairsville, Georgia 30103, United States
  • GSK Investigational Site
    Columbus, Georgia 31904, United States
  • GSK Investigational Site
    Lexington, Kentucky 40509-1801, United States
  • GSK Investigational Site
    Owensboro, Kentucky 42301, United States
  • GSK Investigational Site
    New Orleans, Louisiana 34452, United States
  • GSK Investigational Site
    Glenn Dale, Maryland 20769, United States
  • GSK Investigational Site
    Towson, Maryland 21204, United States
  • GSK Investigational Site
    Ann Arbor, Michigan 48103, United States
  • GSK Investigational Site
    Linwood, Minnesota 55092, United States
  • GSK Investigational Site
    Rochester, Minnesota 55905-0001, United States
  • GSK Investigational Site
    Henderson, Nevada 89052-5015, United States
  • GSK Investigational Site
    Rochester, New York 14607, United States
  • GSK Investigational Site
    Schenectady, New York 12308, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19141, United States
  • GSK Investigational Site
    Union, South Carolina 29379-7409, United States
  • GSK Investigational Site
    Cypress, Texas 77429-1439, United States
  • GSK Investigational Site
    Kerrville, Texas 78028, United States
  • GSK Investigational Site
    McKinney, Texas 75069, United States
  • GSK Investigational Site
    Kortrijk, 8500, Belgium
  • GSK Investigational Site
    Liège, 4000, Belgium
  • GSK Investigational Site
    Calgary, Alberta T3B0M3, Canada
  • GSK Investigational Site
    Calgary, Alberta, Canada
  • GSK Investigational Site
    Winnipeg, Manitoba R3L 1Z5, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 1E2, Canada
  • GSK Investigational Site
    Brest, 29200, France
  • GSK Investigational Site
    Cannes, 06614, France
  • GSK Investigational Site
    Lille, 59000, France
  • GSK Investigational Site
    Lyon, 69004, France
  • GSK Investigational Site
    Strasbourg, 67091, France
  • GSK Investigational Site
    Toulouse, 31059, France
  • GSK Investigational Site
    Darmstadt, Hesse 64283, Germany
  • GSK Investigational Site
    Frankfurt am Main, Hesse 60389, Germany
  • GSK Investigational Site
    Aachen, North Rhine-Westphalia 52074, Germany
  • GSK Investigational Site
    Bonn, 53119, Germany
  • GSK Investigational Site
    Hohenstein-Ernsttal, 9337, Germany
  • GSK Investigational Site
    Schleswig, 53123, Germany
  • GSK Investigational Site
    Genova, 16132, Italy
  • GSK Investigational Site
    Monserrato CA, 09042, Italy
  • GSK Investigational Site
    Naples, 80131, Italy
  • GSK Investigational Site
    Pieve Di Soligo TV, 131044, Italy
  • GSK Investigational Site
    Roma, 00128, Italy
  • GSK Investigational Site
    Roma, 161, Italy
  • GSK Investigational Site
    Rozzano, 20089, Italy
  • GSK Investigational Site
    Verona, 37126, Italy
  • GSK Investigational Site
    Gifu, 509-6134, Japan
  • GSK Investigational Site
    Kagawa, 760-0018, Japan
  • GSK Investigational Site
    Tokyo, 105-0003, Japan
  • GSK Investigational Site
    Tokyo, 142-8666, Japan
  • GSK Investigational Site
    Tokyo, 173-8606, Japan
  • GSK Investigational Site
    ?Od?, 90-153, Poland
  • GSK Investigational Site
    Gdansk, 80-214, Poland
  • GSK Investigational Site
    Lodz, 92-213, Poland
  • GSK Investigational Site
    Barcelona, 08025, Spain
  • GSK Investigational Site
    Girona, 17005, Spain
  • GSK Investigational Site
    Valencia, 46015, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Feb 2026, 22 months.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 22 months is close to that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Jan 2025 → Feb 2026 and completion Jun 2028 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2023
First posted
Sep 18, 2023
StartActual
Mar 20, 2024
Primary completionActual
Feb 12, 2026was Jan 2025
CompletionEst.
Mar 31, 2027was Jun 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 4 sites removed
Show 4 added (3 Germany, 1 United States)
  • GSK Investigational Site · Linwood, United States
  • GSK Investigational Site · Darmstadt, Germany
  • GSK Investigational Site · Frankfurt am Main, Germany
  • GSK Investigational Site · Aachen, Germany
Show 4 removed
  • GSK Investigational Site · Linwood, United States
  • GSK Investigational Site · Aachen, Germany
  • GSK Investigational Site · Darmstadt, Germany
  • GSK Investigational Site · Frankfurt, Germany
Nov 10, 2026
Primary completion
Jan 31, 2025→Feb 12, 2026
Nov 10, 2026
Study completion
Jun 14, 2028→Mar 31, 2027
Nov 10, 2026
Enrollment
336 (estimated)→177 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    4 sites added, 4 sites removed
    Show 4 added (3 Germany, 1 United States)
    • GSK Investigational Site · Linwood, United States
    • GSK Investigational Site · Darmstadt, Germany
    • GSK Investigational Site · Frankfurt am Main, Germany
    • GSK Investigational Site · Aachen, Germany
    Show 4 removed
    • GSK Investigational Site · Linwood, United States
    • GSK Investigational Site · Aachen, Germany
    • GSK Investigational Site · Darmstadt, Germany
    • GSK Investigational Site · Frankfurt, Germany
    Primary completion Jan 31, 2025→Feb 12, 2026
    Study completion Jun 14, 2028→Mar 31, 2027
    Enrollment 336 (estimated)→177 (actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06041386
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 18, 2023
Start date
Mar 20, 2024
Primary completion
Feb 12, 2026
Completion
Mar 31, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mepolizumab

Start the discussion